• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS)

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


OSB Lead-Short to Mid-Term f/u of New US Patients

Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Study Status Progress Inadequate
Application Number P150030 / PAS002
Date Current Protocol Accepted 11/30/2017
Study Name OSB Lead-Short to Mid-Term f/u of New US Patients
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group Historical Control
Analysis Type Analytical
Study Population Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Design Description The study design is prospective cohort, new enrollment.
Study Population Description US patients who receive the device in the post market environment. The comparator group is comprised of patients in the European premarket cohort.
Sample Size A total of 183 study subjects will be enrolled.
Data Collection The primary endpoint is overall study success at 3 years post procedure. Success is defined the same way it was in the premarket cohort, to allow comparison. Overall Success is defined as:

No component revision, and

Modified Harris Hip Score (mHHS) of at least 80 points, and

No radiographic failure, defined as:

No radiolucencies greater than 2 mm in 50% or more in any of the cup or stem zones, no femoral or acetabular subsidence greater than or equal to 5 mm from baseline, and no acetabular cup inclination changes greater than 4 degree.

Secondary endpoints include clinical assessments of pain and function using the Harris Hip Score, radiographic findings and implant survivorship.
Follow-up Visits and Length of Follow-up Patients will be followed for 3 years
Interim or Final Data Summary
Interim Safety Information Number of study sites enrolled No study sites have yet been enrolled.

Number of subjects enrolled No study subjects have yet been enrolled.

Follow-up rate N/a as no study subjects have yet been enrolled.

Summary of Interim Results No study data has yet been collected.

Strengths and Weaknesses A strength of the study is an adequate sample size. A weakness of the study is the absence of long-term follow-up of study subjects.

OSB Lead-Short to Mid-Term f/u of New US Patients Schedule

Report Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
six month report 04/17/2017 04/17/2017 On Time
one year report 10/17/2017 10/12/2017 On Time
18 month report 04/17/2018 04/16/2018 On Time
two year report 10/17/2018    
three year report 10/17/2019    
four year report 10/16/2020    
five year report 10/16/2021    

Contact Us

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD

Phone: (301) 796-6134
Fax: (301) 847-8140

Related Links